Financial | Myriad Genetics, Inc.

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

Investor Relations Contact

Matt Scalo
801.584.3532
matt.scalo@myriad.com

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

Investor Relations Contact

Stock Quote